Roivant Sciences
Mayukh Sukhatme serves as President and Chief Investment Officer of Roivant. In that role he oversees the creation and support of biopharmaceutical companies in the Roivant family. Dr. Sukhatme joined Roivant in 2015 and previously served as Chief Business Officer and President of Roivant Pharma.
From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.
This person is not in any offices
Roivant Sciences
56 followers
Roivant Sciences is a biopharmaceutical company focused on realizing the full value of promising drug candidates to improve the lives of patients.